142 assets in Cutaneous Melanoma

Therapeutic assets addressing Cutaneous Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Navitoclax Cutaneous Melanoma	National Cancer Institute (NCI)	P1/2	CC (45)
or502 Cutaneous Melanoma	OncoResponse, Inc.	P1/2	CC (45)
Rtx-224 Cutaneous Melanoma	Rubius Therapeutics	P1/2	CC (45)
SL-28 Cutaneous Melanoma	Second Life Therapeutics	P1/2	CC (45)
Trastuzumab Deruxtecan Cutaneous Melanoma	GI Innovation, Inc.	P1/2	CC (45)
Tbio-4101 Cutaneous Melanoma	Turnstone Biologics, Corp.	P1	CC (44)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes Cutaneous Melanoma	Anusha Kalbasi	P1	CC (43)
Avelumab Cutaneous Melanoma	Aulos Bioscience, Inc.	P1/2	CC (43)
Cefazolin Cutaneous Melanoma	M.D. Anderson Cancer Center	P1	CC (43)
Fludeoxyglucose Cutaneous Melanoma	Children's Oncology Group	P1	CC (43)
Hafnium Oxide Cutaneous Melanoma	Nanobiotix	P1	CC (43)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells Cutaneous Melanoma	Anusha Kalbasi	P1	CC (43)
mk-2206 Cutaneous Melanoma	National Cancer Institute (NCI)	P1	CC (43)
Pepinemab Cutaneous Melanoma	Emory University	P1	CC (43)
Quadrivalent Inactivated Influenza Vaccine Cutaneous Melanoma	Carlo Contreras	P1	CC (43)
Alpelisib Cutaneous Melanoma	M.D. Anderson Cancer Center	P1	CC (41)
Fermented Wheat Germ Extract Cutaneous Melanoma	University of California, Davis	P1	CC (41)
[Ga-68]-Pnt6555 Cutaneous Melanoma	POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company	P1	CC (41)
Ipn 60090 Cutaneous Melanoma	M.D. Anderson Cancer Center	P1	CC (41)
kfa115 Cutaneous Melanoma	Novartis Pharmaceuticals	P1	CC (41)
Kup-101A Cutaneous Melanoma	Kupando GmbH	P1	CC (41)
[Lu-177]-Pnt6555 Cutaneous Melanoma	POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company	P1	CC (41)
mbs8 Cutaneous Melanoma	MonTa Biosciences ApS	P1	CC (41)
Mrna-4203 Cutaneous Melanoma	Immatics US, Inc.	P1	CC (41)
Neovax Cutaneous Melanoma	Dana-Farber Cancer Institute	P1	CC (41)
Pepticrad-1 Cutaneous Melanoma	Valo Therapeutics Oy	P1	CC (41)
pf-08046033 Cutaneous Melanoma	Pfizer	P1	CC (41)
pf-08046049 Cutaneous Melanoma	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (41)
Sonidegib Cutaneous Melanoma	Mayo Clinic	P1	CC (41)
Tacrolimus Cutaneous Melanoma	National Cancer Institute (NCI)	P1	CC (41)
Tgi-5 Cutaneous Melanoma	Hefei TG ImmunoPharma Co., Ltd.	P1	CC (41)
TH19P01-DOCETAXEL Cutaneous Melanoma	Theratechnologies	P1	CC (41)
Zirconium Zr 89 Crefmirlimab Berdoxam Cutaneous Melanoma	Abramson Cancer Center at Penn Medicine	Early P1	CC (41)
Immunoglobulin G1, Anti-(Human Programmed Death-Ligand 1) (Human Monoclonal Sti-3031 .Gamma.1-Chain), Disulfide With Human Monoclonal Sti-3031 .Lambda.-Chain, Dimer Cutaneous Melanoma	Mayo Clinic	P1	CC (40)
177lu-rad204 Cutaneous Melanoma	Radiopharm Theranostics, Ltd	Early P1	C (38)
E-6201 Cutaneous Melanoma	Mayo Clinic	P1	D (27)
Atorvastatin Cutaneous Melanoma	OHSU Knight Cancer Institute	P2	NR ()
Infusion Of Hs-It101 Cutaneous Melanoma	Qingdao Sino-Cell Biomedicine Co., Ltd.	P2	NR ()
Itil-168 Cutaneous Melanoma	Instil Bio	P2	NR ()
ph-762 Cutaneous Melanoma	Phio Pharmaceuticals Inc.	P1	NR ()
Xmab808 Cutaneous Melanoma	Xencor, Inc.	P1	NR ()

Showing 101 to 142 of 142 assets

PreviousPage 3 of 3Next